Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000008812
- Lead Sponsor
- Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use 2)patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method mprovement of major clinical signs and symptoms at week 12(fever,abnormal findings of temporal artery, myalgia, serum CRP, ESR, abnormal radiological findings of the affected vessels)
- Secondary Outcome Measures
Name Time Method Improvement of major clinical signs at week 52, relapse rate and adverse events during 52 weeks